MYCN and neuroblastoma: During the internal validation process using the GSE49710 dataset, an interesting result emerged: regardless of the 3-year or 5-year EFS or OS, the signature we constructed appeared to have a better fit for predicting the prognosis of NB patients compared to evaluating the prognosis based on MYCN amplification (AUC values of 3 years and 5 years EFS: 0.718 vs. 0.620; 0.709 vs. 0.603, AUC values of 3 years and 5 years OS: 0.824 vs.0.769; 0.793 vs.0.692, respectively), as shown in Figures 3B, C, F, G).